Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-na ve HIV-1-infected patients

被引：5
|
作者：
Zolopa, A. [1 ]
Gallant, J. [2 ]
Cohen, C. [3 ]
Sax, P. [4 ]
Dejesus, E. [5 ]
Mills, A. [6 ]
Wohl, D. [7 ]
Liu, H. [8 ]
Rhee, M. [8 ]
Szwarcberg, J. [8 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Johns Hopkins Sch Med, Baltimore, MD USA
[3] Community Res Initiat New England, Boston, MA USA
[4] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
[5] Orlando Immunol Ctr, Orlando, FL USA
[6] Anthony Mills MD Inc, Los Angeles, CA USA
[7] Univ N Carolina, Chapel Hill, NC USA
[8] Gilead Sci, Foster City, CA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2012年 / 15卷
关键词：
D O I：
10.7448/IAS.15.6.18219
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [41] Clinical efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide and lamivudine/dolutegravir in the treatment-na?ve patients with acquired immunodeficiency syndrome
    王江蓉
    [J]. China Medical Abstracts(Internal Medicine), 2024, 41 (03) : 157
  • [42] Simplification to Single Tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir DF from Multi-tablet Ritonavir-Boosted Protease Inhibitor Plus Coformulated Emtricitabine and Tenofovir DF Regimens: Week 96 Results of STRATEGY-PI (vol 18, pg 118, 2017)
    Doroana, Manuela
    [J]. HIV CLINICAL TRIALS, 2018, 19 (04): : 163 - 163
  • [43] Effectiveness and safety of a single-tablet regimen of emtricitabine/efavirenz/tenofovir in HIV-1-infected patients in infectious diseases department
    Xerinda, S.
    Neves, N.
    Santos, S.
    Pineiro, C.
    Poinhos, R.
    Soares, J.
    Serrao, R.
    Sarmento, A.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 168 - 169
  • [44] The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients
    Cassetti, Isabel
    Madruga, Jose Valdez R.
    Suleiman, Jamal Muhamad A. H.
    Etzel, Arnaldo
    Zhong, Lijie
    Cheng, Andrew K.
    Enejosa, Jeffrey
    [J]. HIV CLINICAL TRIALS, 2007, 8 (03): : 164 - 172
  • [45] Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
    Cid-Silva, Purificacion
    Fernandez-Bargiela, Noelia
    Margusino-Framinan, Luis
    Balboa-Barreiro, Vanesa
    Mena-De-Cea, Alvaro
    Lopez-Calvo, Soledad
    Vazquez-Rodriguez, Pilar
    Martin-Herranz, Isabel
    Miguez-Rey, Enrique
    Poveda, Eva
    Castro-Iglesias, Angeles
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (04) : 479 - 490
  • [46] Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
    Juday, Timothy
    Correll, Todd
    Anene, Ayanna
    Broder, Michael S.
    Ortendahl, Jesse
    Bentley, Tanya
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2013, 5 : 437 - 445
  • [47] A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results
    Wohl, David
    Oka, Shinichi
    Clumeck, Nathan
    Clarke, Amanda
    Brinson, Cynthia
    Stephens, Jeffrey
    Tashima, Karen
    Arribas, Jose R.
    Rashbaum, Bruce
    Cheret, Antoine
    Brunetta, Jason
    Mussini, Cristina
    Tebas, Pablo
    Sax, Paul E.
    Cheng, Andrew
    Zhong, Lijie
    Callebaut, Christian
    Das, Moupali
    Fordyce, Marshall
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (01) : 58 - 64
  • [48] Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study
    De Castro, Nathalie
    Brun, Alexandre
    Sellier, Pierre
    Hamet, Gwenn
    Mechai, Frederic
    Garrait, Valerie
    Chabrol, Amelie
    Bouldouyre, Marie-Anne
    Froguel, Eric
    Troisvallets, Didier
    Caraux-Paz, Pauline
    Delaugerre, Constance
    Rozenbaum, Willy
    Molina, Jean-Michel
    [J]. AIDS RESEARCH AND THERAPY, 2023, 20 (01)
  • [49] Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
    Cohen, Calvin
    Wohl, David
    Arribas, Jose R.
    Henry, Keith
    Van Lunzen, Jan
    Bloch, Mark
    Towner, William
    Wilkins, Edmund
    Ebrahimi, Ramin
    Porter, Danielle
    White, Kirsten
    Walker, Ivan
    Chuck, Susan
    De-Oertel, Shampa
    Fralich, Todd
    [J]. AIDS, 2014, 28 (07) : 989 - 997
  • [50] Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study
    Nathalie De Castro
    Alexandre Brun
    Pierre Sellier
    Gwenn Hamet
    Frédéric Mechaï
    Valérie Garrait
    Amélie Chabrol
    Marie-Anne Bouldouyre
    Eric Froguel
    Didier Troisvallets
    Pauline Caraux-Paz
    Constance Delaugerre
    Willy Rozenbaum
    Jean-Michel Molina
    [J]. AIDS Research and Therapy, 20
12345